文献速递肝病

磁共振弹性成像预测慢性肝病长期进展与结局的回顾性研究

Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
PubMed 文献 · Hepatology · 2021-12-15

该回顾性研究纳入1269例2007-2009年接受MRE检查的慢性肝病患者,随访至死亡或末次临床接触。基线肝硬度测量(LSM)独立预测非肝硬化患者未来肝硬化发生(校正HR 2.38,p<0.0001)和代偿期肝硬化患者未来失代偿(FIB-4与MELD校正HR 1.22,p<0.0001),对失代偿期肝硬化移植/死亡有预测价值但CPS与MELD校正后不显著。

要点

  • 基线MRE肝硬度独立预测慢性肝病患者未来肝硬化发生与失代偿。
  • 非肝硬化患者肝硬化年发生率约1%,基线LSM预测肝硬化校正HR 2.38。
  • 代偿期肝硬化失代偿预测FIB-4与MELD校正HR 1.22,一致性0.75。

核心结论

  • 基于MRE的肝硬度测量独立预测慢性肝病未来肝硬化发生和失代偿,并对移植/死亡有预测价值。

研究设计与样本

  • 回顾性研究纳入1269例2007-2009年接受MRE检查的慢性肝病患者,随访至死亡或末次临床接触或研究终点。

主要发现

  • 非肝硬化组(n=821)基线LSM中位2.8 kPa,72例(8.8%)发生肝硬化,年发生率约1%,基线LSM预测肝硬化多变量校正HR 2.38(p<0.0001),一致性0.84。
  • 代偿期肝硬化组(n=277)基线LSM中位5.7 kPa,83例(30%)发生失代偿,基线LSM预测失代偿FIB-4与MELD校正HR 1.22(p<0.0001),一致性0.75。
  • 失代偿期肝硬化组(n=171)基线LSM中位6.8 kPa(5.2, 8.4),113例(66%)死亡或移植,基线LSM预测移植或死亡HR 1.11(p=0.013),一致性0.53,但CPS与MELD校正模型不显著(p=0.08)。

关键数值与推荐

  • 非肝硬化组基线LSM中位2.8 kPa,肝硬化发生率8.8%(72/821),年发生率约1%。
  • 代偿期肝硬化组基线LSM中位5.7 kPa,失代偿发生率30%(83/277)。
  • 失代偿期肝硬化组基线LSM中位6.8 kPa(5.2, 8.4),死亡或移植发生率66%(113/171)。
  • 每1-kPa LSM增加预测肝硬化的多变量校正HR 2.38(p<0.0001),一致性0.84。
  • 每1-kPa LSM增加预测失代偿的FIB-4与MELD校正HR 1.22(p<0.0001),一致性0.75。

临床怎么用

  • MRE肝硬度可用于慢性肝病患者风险分层,辅助预测肝硬化进展和失代偿风险。
  • 对失代偿期肝硬化患者,MRE预测移植/死亡的价值在CPS和MELD校正后不显著,需结合其他指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although magnetic resonance elastography (MRE) has been well-established for detecting and staging liver fibrosis, its prognostic role in determining outcomes of chronic liver disease (CLD) is mostly unknown. APPROACH AND RESULTS: This retrospective study consisted of 1269 subjects who underwent MRE between 2007 and 2009 and followed up until death or last known clinical encounter or end of study period. Charts were reviewed for cirrhosis development, decompensation, and transplant or death. The cohort was split into baseline noncirrhosis (group 1), compensated cirrhosis (group 2), and decompensated cirrhosis (group 3). Cox-regression analysis with age, sex, splenomegaly, CLD etiology, Child-Pugh Score (CPS), Fibrosis-4 Index (FIB-4) score, and Model for End-Stage Liver Disease (MELD)-adjusted HR for every 1-kPa increase in liver stiffness measurement (LSM) were used to assess the predictive performance of MRE on outcomes. Group 1 (n = 821) had baseline median LSM of 2.8 kPa, and cirrhosis developed in 72 (8.8%) subjects with an overall rate of about 1% cirrhosis/year. Baseline LSM predicted the future cirrhosis with multivariable adjusted HR of 2.38 (p < 0.0001) (concordance, 0.84). In group 2 (n = 277) with baseline median LSM of 5.7 kPa, 83 (30%) subjects developed decompensation. Baseline LSM predicted the future decompensation in cirrhosis with FIB-4 and MELD-adjusted HR of 1.22 (p < 0.0001) (concordance, 0.75). In group 3 (n = 171) with median baseline LSM of 6.8 kPa (5.2, 8.4), 113 (66%) subjects had either death or transplant. Baseline LSM predicted the future transplant or death with HR of 1.11 (p = 0.013) (concordance 0.53) but not in CPS and MELD-adjusted models (p = 0.08). CONCLUSION: MRE-based LSM is independently predictive of development of future cirrhosis and decompensation, and has predictive value in future transplant/death in patients with CLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gidener T, Yin M, Dierkhising RA, et al. Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study. Hepatology. 2021. PMID: 34510513. doi:10.1002/hep.32151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。